menu
    • menu
    [{"orgOrder":0,"company":"Vascarta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Immuno","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Inapplicable"},{"orgOrder":0,"company":"Vascarta","sponsor":"CUNY","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Collaboration","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ CUNY","highestDevelopmentStatusID":"4","companyTruncated":"Vascarta \/ CUNY"},{"orgOrder":0,"company":"Vascarta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vascarta

    Menu

    Vascarta

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vascarta

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Vascarta

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Curcumin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vascarta Begins Phase 1 Proof of Concept Trial for VAS-101 in Sickle Cell

                            Details : VAS-101 is a topical curcumin formulation, which is being evaluated in the early-satge clinical studies for the treatment of Sickle Cell Disease.

                            Product Name : VAS-101

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Curcumin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vascarta

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Vascarta

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Curcumin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vascarta Commences a Phase I Clinical Study of VAS101 in Osteoarthritis

                            Details : VAS101 is a highly concentrated curcumin gel formulation that employs a patented topical/transdermal delivery platform. It is being evaluated for the treatment of knee osteoarthritis.

                            Product Name : VAS101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Curcumin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vascarta

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Vascarta

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine,Curcumin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : CUNY

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vascarta and CUNY Collaborate to Improve Chemotherapy Efficacy and Safety

                            Details : The collaboration aims to advance the clinical development of a therapy that links anti-cancer agents, such as Gemzar (gemcitabine), with curcumin to enhance the effectiveness in treating cancer.

                            Product Name : Gemzar

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : Gemcitabine,Curcumin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : CUNY

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth